docetaxel

Docetaxel (RP-56976), a semi-synthetic analog of paclitaxel, is a microtubule depolymerization inhibitor (IC50=0.2 μM) that attenuates the effects of bcl-2 and bcl-xL gene expression and exhibits apoptosis-inducing, anti-tumor activity.

Docetaxel trihydrate (RP-56976 Trihydrate) is an antineoplastic agent that has a unique mechanism of action as an inhibitor of cellular mitosis and that currently plays a central role in the therapy of many solid tumor including breast and lung cancer. Therapy with docetaxel has been associated with a low rate of serum enzyme elevations and rarely to instances of acute hepatic necrosis generally due to severe hypersensitivity reactions or sepsis.

7-Epi-10-oxo-docetaxel (Docetaxel Impurity 2) is a docetaxel impurity identified by HPLC.

Docetaxel-d9 is a deuterated compound of Docetaxel. Docetaxel has a CAS number of 114977-28-5. Docetaxel is a microtubule inhibitor that inhibits microtubule disassembly (IC50: 0.2 μM).

10-Oxo Docetaxel is a Docetaxel intermediate having remarkable antitumor properties.

7-Epi-10-oxo-docetaxel (7-Epitaxotere) is a impurity of docetaxel.

Sudocetaxel is a compound that serves as a microtubule depolymerization inhibitor, specifically designed for the pH-sensitive delivery of docetaxel.

Sudocetaxel zendusortide functions as an antineoplastic [1].

Cabazitaxel (taxoid XRP6258) is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after failure of docetaxel.

DUPA(OtBu)-OH is a precursor of DUPA, which is used as a targeting moiety to actively deliver Docetaxel (DTX) for treating Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer, with PSMA showing high affinity for DUPA (Ki = 8 nM).

Hydroxy-PEG10-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG10-Boc can be conjugated to Paclitaxel or docetaxel [2].

Larotaxel (XRP9881) is a taxane analogue with anticancer activity that promotes tubulin assembly and stabilizes microtubules, inducing apoptosis. It crosses the blood-brain barrier and has a higher affinity for Docetaxel than P-glycoprotein 1, making it useful for studying breast and bladder cancer.

Docetaxal (10-Acetyl docetaxel) is an analogue of Docetaxel, which is a microtubule inhibitor. Docetaxal can be used in cancer research.

Tunlametinib is a highly selective, orally bioavailable small molecule inhibitor of MEK1 and MEK2 kinases with a reported IC50 value of 1.9 nM for MEK1. Tunlametinib exerts its antitumor effects by blocking the oncogenic RAS-RAF-MEK-ERK signaling pathway, thereby inducing tumor cell cycle arrest and promoting apoptosis, Tunlametinib demonstrates strong inhibitory activity against various RAS/RAF-mutant cancer cells such as those harboring BRAF V600E or KRAS G12C mutations, shows synergistic effects in combination with BRAF/KRASG12C/SHP2 inhibitors and Docetaxel, and is used in targeted therapy for RAS/RAF-driven cancers including melanoma, colorectal cancer, and non-small cell lung cancer (NSCLC).

ALDH3A1-IN-1 (Compound 18) is a potent ALDH3A1 inhibitor with an IC 50 of 1.61 μM. It is more effective than DEAB against patient-derived primary prostate tumor epithelial cells, both as a single agent and in combination with docetaxel [1].

Gemcitabine-ibandronate (GEM–IB), a conjugate of gemcitabine (GEM)-5'-phosphate with ibandronate (IB), exhibits efficacy both as a monotherapy and synergistically with Docetaxel (DTX), resulting in diminished tumor burden, maintained bone structure, and enhanced survival in a murine osteosarcoma (OS) model [1].

CYP1B1-IN-7 is a selective and potent CYP1B1 inhibitor showing cytotoxic effects in docetaxel-resistant CYP1B1 overexpressing MCF-7 cell lines, and can be used in synergistic treatment of cancer with anticancer compounds.

Bisdemethoxycurcumin is a natural curcumin derivative that activates the AMPKα pathway to attenuate LPS-induced acute lung injury; reversibly inhibits tyrosinase and possesses anti-browning ability; enhances the antiprostate cancer efficacy of docetaxel (DTX); targets cellular pathways involved in oxidative stress and apoptosis; and is an anticancer agent.

CXCR4 antagonist; induces mitotic catastrophe in ovarian cancer cells. Displays additive cytotoxic effects when given with taxol. Enhances the efficacy of docetaxel in a mouse model.

DTX-P7 is a peptide drug conjugate (PDC) composed of Docetaxel (DTX) and a heptapeptide (P7), which induces the unfolded protein response and subsequent apoptosis by degrading Hsp90.